Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dalton, Oncovir sign manufacturing services agreement
The Cancer Vaccine Acceleration Fund (CVAF) – a joint initiative between the Cancer Research Institute and the Ludwig Institute for Cancer Research – has completed a new investment
The Cancer Vaccine Acceleration Fund (CVAF) – a joint initiative between the Cancer Research Institute and the Ludwig Institute for Cancer Research – has completed a new investment
Almost $1.7bn charges before taxes were due to a setback for its experimental blood clot preventer vorapaxar. However, Merck beat forecasts on strong sales growth from its key
The CRADA will allow the WRAIR to conduct preclinical testing on a novel compound derived from Concert’s DCE Platform (deuterated chemical entity platform) for seizure protection associated with
Both studies were 12-week, double-blinded, placebo-controlled clinical trials conducted under the regulatory guidelines of Health Canada. Based on analysis of the data, both the primary and secondary efficacy
CSRMI Director Clive Svendsen and his team led by Dhruv Sareen were given this grant to invent a new pharmaceutical discovery process that employs pluripotent stem cells in
The sale buoyed hopes that Glaxo would restart a share buyback programme to bolster its share price, and also freed cash for Glaxo to pay a £2.2bn net
Net sales decreased 6% to $992m in the fourth quarter of 2010. Specialty Injectable Pharmaceuticals sales were stable despite the year-over-year impact of the temporary discontinuation of US
The study will evaluate several dose strengths of VIBEX MTX which is being developed for the treatment of rheumatoid arthritis. VIBEX MTX is Antares’ proprietary – wholly owned
Rabeprazole sodium extended-release capsules, 50 mg, is an investigational proton pump inhibitor, which is under review for the healing and long-term maintenance of healing and symptom resolution of
The studies achieved a median set-up time of 54 days compared with an average of 140 days for all commercial studies in the NHS Research’s database of active